Evidence map›Paper›PMID 26579842›Full record

ArticleJournal of lower genital tract disease2016

An Insight Into Cervical Cancer Screening and Treatment Capacity in Sub Saharan Africa.

Jenell S Coleman, Michelle S Cespedes, Susan Cu-Uvin, Rose J Kosgei, May Maloba, Jean Anderson, Timothy Wilkin, Antoine Jaquet, Julia Bohlius, Kathryn Anastos and 1 more

Abstract read
In one paragraph

Article in Journal of lower genital tract disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jenell S Coleman1Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD; 2Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; 3The Warren Alpert Medical School of Brown University, Providence, RI; 4Department of Obstetrics and Gynecology, University of Nairobi; 5Kenya Medical Research Institute FACES, Nairobi, Kenya; 6 Division of Infectious Diseases, Weill Cornell Medical College, New York, NY; 7Université Bordeaux and 8INSERM, ISPED, Centre INSERM U897-Epidémiologie-Bio statistique, Bordeaux, France; 9Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 10Department of Medicine, Montefiore Medical Center, Bronx, NY; and 11Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN.
Michelle S Cespedes
Susan Cu-Uvin
Rose J Kosgei
May Maloba
Jean Anderson
Timothy Wilkin
Antoine Jaquet
Julia Bohlius
Kathryn Anastos
Kara Wools-Kaloustian

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AGGREY SEMWENDERO SEMEERE, Kara Kay Wools-Kaloustian · 2006 to 2026
$57.7M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
WADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9M
Core-010UL1TR001073 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, SHAMOON, HARRY · 2013 to 2017
$21.3M
Immunology/Pathology CoreP30AI051519 · NIAID · YESHIVA UNIVERSITY · PI GOLDSTEIN, HARRIS · 2003 to 2013
$18.6M
Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTUU01AI069472 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KURITZKES, DANIEL R. · 2007 to 2011
$15.4M
NCATS NIH HHS UL1 TR001073NIAID NIH HHS 5P30AI027757NIAID NIH HHS 5P30AI027763NIAID NIH HHS 5P30AI036219NIAID NIH HHS 5P30AI050410NIAID NIH HHS 5P30AI051519NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI051519NIAID NIH HHS P30 AI060354NIAID NIH HHS P30AI060354NIAID NIH HHS P30 AI094189NIAID NIH HHS P30AI094189NIAID NIH HHS P30AI42853NIAID NIH HHS U01 AI069472NIAID NIH HHS U01 AI069911NIAID NIH HHS U01AI069911NIAID NIH HHS U01 AI069919NIAID NIH HHS U01AI069919NIAID NIH HHS U10AI069472NIAID NIH HHS UM1 AI069472PHS HHS UM1 A1068636
6 · The paper itself

Abstract

objectiveApproximately 85% of cervical cancer cases and deaths occur in resource-constrained countries where best practices for prevention, particularly for women with HIV infection, still need to be developed. The aim of this study was to assess cervical cancer prevention capacity in select HIV clinics located in resource-constrained countries. MATERIALS AND

methodsA cross-sectional survey of sub-Saharan African sites of 4 National Institutes of Health-funded HIV/AIDS networks was conducted. Sites were surveyed on the availability of cervical cancer screening and treatment among women with HIV infection and without HIV infection. Descriptive statistics and χ or Fisher exact test were used as appropriate.

resultsFifty-one (65%) of 78 sites responded. Access to cervical cancer screening was reported by 49 sites (96%). Of these sites, 39 (80%) performed screening on-site. Central African sites were less likely to have screening on-site (p = .02) versus other areas. Visual inspection with acetic acid and Pap testing were the most commonly available on-site screening methods at 31 (79%) and 26 (67%) sites, respectively. High-risk HPV testing was available at 29% of sites with visual inspection with acetic acid and 50% of sites with Pap testing. Cryotherapy and radical hysterectomy were the most commonly available on-site treatment methods for premalignant and malignant lesions at 29 (74%) and 18 (46%) sites, respectively.

conclusionsDespite limited resources, most sites surveyed had the capacity to perform cervical cancer screening and treatment. The existing infrastructure of HIV clinical and research sites may provide the ideal framework for scale-up of cervical cancer prevention in resource-constrained countries with a high burden of cervical dysplasia.

Indexed as

Early Detection of CancerHealth FacilitiesSurgical Procedures, OperativeAfrica South of the SaharaCross-Sectional StudiesFemaleHealth Services ResearchHumansUterine Cervical Neoplasms

Identifiers

PMID26579842
PMCPMC4691409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.